I recently reported on data collected from Fitbit activity trackers. Fitbit has compiled 150 billion hours of data on the resting heart rate (RHR) of tens of millions of people around the world who used a Fitbit. Can this type of data help researchers, especially cardiologists, conduct better clinical trials on heart patients in the future?
David Pogue, a tech columnist for Yahoo Finance, notes Fitbit has collected 150 billion hours of heart-rate data from tens of millions of people all over the world. In January, Fitbit gave Pogue a deep dive into the data it collected. The finding may bode well for the use of activity trackers in future trials.
A new brief by CB Insights focuses on AI and its potential to transform clinical trials. A makeover of the $65 billion clinical trials market is well overdue. With all of the issues that seem to be preventing more efficient trials, will AI be the technology that finally streamlines the process?
Adverse events (a suspected reaction to the API or to the API in combination with prescribed medicines or environmental factors) are, naturally, a challenging situation for patients in a clinical trial and may, in rare cases, become severe or even fatal. For sponsors, contract research organizations (CROs), and logistics partners, early notification and accurate information is vital to understanding and responding to a suspected adverse event. What happens if the patient goes off protocol and turns to social media?
The Deloitte Center for Health Solutions recently interviewed 43 biopharmaceutical industry stakeholders to explore where the industry sees value and opportunities for using digital technologies in the clinical development process; understand reasons behind the relatively slow pace of digital adoption; and uncover strategies to overcome barriers and accelerate the use of digital in clinical trials. This is the second of two articles that shares interview findings and insights published in the new Deloitte report, Digital R&D: Transforming the future of clinical development.
Sudip Parikh, SVP & managing director, Americas at DIA Global, sees two trends that will continue to have a profound impact on potentially powerful new treatments and the clinical trials that make them possible. Both will be front and center at DIA’s 2018 Annual Meeting.
Advancements in biosensor technology are becoming increasingly common in the consumer space, with wrists adorned with Fitbits or similar devices, clothing embedded with “intelligent” fibers, and personal safety devices seen in healthcare facilities across the nation. Our culture is increasingly accustomed to tracking health metrics through smartphones and simple recreational wearables. In the pharmaceutical space, we are now seeing where success in the consumer segment can translate to value-adds for clinical trials.
The challenge to recruit and retain numbers of patients for Phase 3 industry-sponsored trials is not new to the industry. In fact, 48 percent of sites miss their enrollment targets and 80 percent of trials are delayed due to recruitment, but there are new opportunities to achieve recruitment goals while also minimizing dropout.
The Deloitte Center for Health Solutions recently interviewed 43 biopharmaceutical industry stakeholders to explore where the industry sees value and opportunities for using digital technologies in the clinical development process; understand reasons behind the relatively slow pace of digital adoption; and uncover strategies to overcome barriers and accelerate the use of digital in clinical trials. This is the first of two articles that shares interview findings and insights published in the new Deloitte Center for Health Solutions report Digital R&D: Transforming the future of clinical development.
Getting drugs to cross the blood-brain barrier can be a challenge for sponsor companies. Kazia Therapeutics is working on a treatment for glioblastoma, the most common and aggressive form of brain cancer. Kazia will use an adaptive approach in a Phase 2 trial using a product which was designed by Genentech to cross the blood-brain barrier.
|
|
|
|
|
|
|
|
|